<VariationArchive RecordType="classified" VariationID="597005" VariationName="NM_000152.5(GAA):c.2655_2656del (p.Val886fs)" VariationType="Deletion" Accession="VCV000597005" Version="6" NumberOfSubmissions="2" NumberOfSubmitters="2" DateLastUpdated="2023-04-02" DateCreated="2018-12-16" MostRecentSubmission="2021-12-12">
  <RecordStatus>current</RecordStatus>
  <Species>Homo sapiens</Species>
  <ClassifiedRecord>
    <SimpleAllele AlleleID="588066" VariationID="597005">
      <GeneList>
        <Gene Symbol="GAA" FullName="alpha glucosidase" GeneID="2548" HGNC_ID="HGNC:4065" Source="submitted" RelationshipType="within single gene">
          <Location>
            <CytogeneticLocation>17q25.3</CytogeneticLocation>
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="17" Accession="NC_000017.11" start="80101581" stop="80119881" display_start="80101581" display_stop="80119881" Strand="+" />
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="17" Accession="NW_025791802.1" start="126287" stop="144587" display_start="126287" display_stop="144587" Strand="+" />
            <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="17" Accession="NC_000017.10" start="78075354" stop="78093678" display_start="78075354" display_stop="78093678" Strand="+" />
          </Location>
          <OMIM>606800</OMIM>
          <Property>gene_acmg_incidental_2021</Property>
          <Property>gene_acmg_incidental_2022</Property>
        </Gene>
      </GeneList>
      <Name>NM_000152.5(GAA):c.2655_2656del (p.Val886fs)</Name>
      <CanonicalSPDI>NC_000017.11:80118660:CG:</CanonicalSPDI>
      <VariantType>Deletion</VariantType>
      <Location>
        <CytogeneticLocation>17q25.3</CytogeneticLocation>
        <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" forDisplay="true" AssemblyStatus="current" Chr="17" Accession="NC_000017.11" start="80118661" stop="80118662" display_start="80118661" display_stop="80118662" variantLength="2" positionVCF="80118660" referenceAlleleVCF="TCG" alternateAlleleVCF="T" />
        <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="17" Accession="NC_000017.10" start="78092460" stop="78092461" display_start="78092460" display_stop="78092461" variantLength="2" positionVCF="78092459" referenceAlleleVCF="TCG" alternateAlleleVCF="T" />
      </Location>
      <OtherNameList>
        <Name>NM_000152.5(GAA):c.2655_2656del</Name>
        <Name>p.Val886fs</Name>
      </OtherNameList>
      <ProteinChange>V886fs</ProteinChange>
      <HGVSlist>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="LRG_673" sequenceAccession="LRG_673" change="g.22106_22107del">
            <Expression>LRG_673:g.22106_22107del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Assembly="GRCh37" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000017.10" sequenceAccession="NC_000017" sequenceVersion="10" change="g.78092460_78092461del" Assembly="GRCh37">
            <Expression>NC_000017.10:g.78092460_78092461del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Assembly="GRCh38" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000017.11" sequenceAccession="NC_000017" sequenceVersion="11" change="g.80118661_80118662del" Assembly="GRCh38">
            <Expression>NC_000017.11:g.80118661_80118662del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="NG_009822.1" sequenceAccession="NG_009822" sequenceVersion="1" change="g.22106_22107del">
            <Expression>NG_009822.1:g.22106_22107del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_000152.5" sequenceAccession="NM_000152" sequenceVersion="5" change="c.2655_2656del" MANESelect="true">
            <Expression>NM_000152.5:c.2655_2656del</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_000143.2" sequenceAccession="NP_000143" sequenceVersion="2" change="p.Val886fs">
            <Expression>NP_000143.2:p.Val886fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_001079803.3" sequenceAccession="NM_001079803" sequenceVersion="3" change="c.2655_2656del">
            <Expression>NM_001079803.3:c.2655_2656del</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_001073271.1" sequenceAccession="NP_001073271" sequenceVersion="1" change="p.Val886fs">
            <Expression>NP_001073271.1:p.Val886fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_001079804.3" sequenceAccession="NM_001079804" sequenceVersion="3" change="c.2655_2656del">
            <Expression>NM_001079804.3:c.2655_2656del</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_001073272.1" sequenceAccession="NP_001073272" sequenceVersion="1" change="p.Val886fs">
            <Expression>NP_001073272.1:p.Val886fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
      </HGVSlist>
      <XRefList>
        <XRef Type="rs" ID="1555603219" DB="dbSNP" />
      </XRefList>
    </SimpleAllele>
    <RCVList>
      <RCVAccession Title="NM_000152.5(GAA):c.2655_2656del (p.Val886fs) AND not provided" Accession="RCV000732997" Version="5">
        <ClassifiedConditionList TraitSetID="9460">
          <ClassifiedCondition DB="MedGen" ID="CN517202">not provided</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description DateLastEvaluated="2018-04-27" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
      <RCVAccession Title="NM_000152.5(GAA):c.2655_2656del (p.Val886fs) AND Glycogen storage disease, type II" Accession="RCV001789710" Version="3">
        <ClassifiedConditionList TraitSetID="1104">
          <ClassifiedCondition DB="MedGen" ID="C0017921">Glycogen storage disease, type II</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>reviewed by expert panel</ReviewStatus>
            <Description DateLastEvaluated="2021-09-01" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
    </RCVList>
    <Classifications>
      <GermlineClassification DateLastEvaluated="2021-09-01" NumberOfSubmissions="2" NumberOfSubmitters="2" DateCreated="2018-12-16" MostRecentSubmission="2021-12-12">
        <ReviewStatus>reviewed by expert panel</ReviewStatus>
        <Description>Pathogenic</Description>
        <Citation Type="general">
          <URL>http://www.egl-eurofins.com/emvclass/emvclass.php?approved_symbol=GAA</URL>
        </Citation>
        <Citation Type="general">
          <URL>https://erepo.clinicalgenome.org/evrepo/ui/interpretation/73dc276a-44f8-4f4e-ad99-3769378ea110</URL>
        </Citation>
        <ConditionList>
          <TraitSet ID="9460" Type="Disease" ContributesToAggregateClassification="false">
            <Trait ID="17556" Type="Disease">
              <Name>
                <ElementValue Type="Preferred">not provided</ElementValue>
                <XRef ID="13DG0619" DB="Developmental Genetics Unit, King Faisal Specialist Hospital &amp; Research Centre" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">none provided</ElementValue>
              </Name>
              <AttributeSet>
                <Attribute Type="public definition">The term 'not provided' is registered in MedGen to support identification of submissions to ClinVar for which no condition was named when assessing the variant. 'not provided' differs from 'not specified', which is used when a variant is asserted to be benign, likely benign, or of uncertain significance for conditions that have not been specified.</Attribute>
              </AttributeSet>
              <XRef ID="CN517202" DB="MedGen" />
            </Trait>
          </TraitSet>
          <TraitSet ID="1104" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="1936" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">Glycogen Storage Disease Type II (Pompe Disease)</ElementValue>
                <XRef ID="NBK1261" DB="GeneReviews" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">ACID ALPHA-GLUCOSIDASE DEFICIENCY</ElementValue>
                <XRef Type="MIM" ID="232300" DB="OMIM" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">GLYCOGENOSIS, GENERALIZED, CARDIAC FORM</ElementValue>
                <XRef Type="MIM" ID="232300" DB="OMIM" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">GSD II</ElementValue>
                <XRef Type="MIM" ID="232300" DB="OMIM" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">POMPE DISEASE</ElementValue>
                <XRef Type="MIM" ID="232300" DB="OMIM" />
              </Name>
              <Name>
                <ElementValue Type="Preferred">Glycogen storage disease, type II</ElementValue>
                <XRef ID="Glycogen+Storage+Disease+Type+2/3122" DB="Genetic Alliance" />
                <XRef ID="237967002" DB="SNOMED CT" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Glucosidase acid-1,4-alpha deficiency</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Glycogen storage disease type 2</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Acid maltase deficiency disease</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Aglucosidase alfa</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Alpha-1,4-glucosidase deficiency</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Cardiomegalia glycogenica diffusa</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Deficiency of alpha-glucosidase</ElementValue>
                <XRef ID="124462004" DB="SNOMED CT" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Deficiency of lysosomal alpha-glucosidase</ElementValue>
              </Name>
              <Symbol>
                <ElementValue Type="Alternate">AMD</ElementValue>
                <XRef Type="MIM" ID="232300" DB="OMIM" />
              </Symbol>
              <Symbol>
                <ElementValue Type="Preferred">GSD2</ElementValue>
                <XRef Type="MIM" ID="232300" DB="OMIM" />
              </Symbol>
              <AttributeSet>
                <Attribute Type="public definition">Pompe disease is classified by age of onset, organ involvement, severity, and rate of progression. Infantile-onset Pompe disease (IOPD; individuals with onset before age 12 months with cardiomyopathy) may be apparent in utero but more typically onset is at the median age of four months with hypotonia, generalized muscle weakness, feeding difficulties, failure to thrive, respiratory distress, and hypertrophic cardiomyopathy. Without treatment by enzyme replacement therapy (ERT), IOPD commonly results in death by age two years from progressive left ventricular outflow obstruction and respiratory insufficiency. Late-onset Pompe disease (LOPD; including: (a) individuals with onset before age 12 months without cardiomyopathy; and (b) all individuals with onset after age 12 months) is characterized by proximal muscle weakness and respiratory insufficiency; clinically significant cardiac involvement is uncommon.</Attribute>
                <XRef ID="NBK1261" DB="GeneReviews" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="2503" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301438</ID>
                <ID Source="BookShelf">NBK1261</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG, 2006">
                <ID Source="pmc">3110959</ID>
              </Citation>
              <Citation Type="general" Abbrev="ESC, 2014">
                <ID Source="PubMed">25173338</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG SF v3.0, 2021">
                <ID Source="PubMed">34012068</ID>
                <ID Source="DOI">10.1038/s41436-021-01172-3</ID>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG ACT, 2022">
                <URL>https://www.acmg.net/PDFLibrary/Pompe.pdf</URL>
                <CitationText>American College of Medical Genetics ACT SHEET, Newborn Screening ACT Sheet- Pompe Disease (Glycogen Storage Disease type II), 2022</CitationText>
              </Citation>
              <Citation Type="general" Abbrev="ACMG SF v3.1, 2022">
                <ID Source="PubMed">35802134</ID>
                <ID Source="DOI">10.1016/j.gim.2022.04.006</ID>
              </Citation>
              <Citation Type="practice guideline" Abbrev="ACMG Algorithm, 2022">
                <URL>https://www.acmg.net/PDFLibrary/Pompe-Algorithm.pdf</URL>
                <CitationText>American College of Medical Genetics and Genomics, Algorithm, Pompe disease: acid alpha-glucosidase deficiency, 2022</CitationText>
              </Citation>
              <XRef ID="365" DB="Orphanet" />
              <XRef ID="C0017921" DB="MedGen" />
              <XRef ID="MONDO:0009290" DB="MONDO" />
              <XRef Type="MIM" ID="232300" DB="OMIM" />
            </Trait>
          </TraitSet>
        </ConditionList>
      </GermlineClassification>
    </Classifications>
    <ClinicalAssertionList>
      <ClinicalAssertion ID="1677994" SubmissionDate="2018-09-19" DateLastUpdated="2018-12-16" DateCreated="2018-12-16">
        <ClinVarSubmissionID localKey="69651_000000" localKeyIsSubmitted="1" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV000861004" DateUpdated="2018-12-16" DateCreated="2018-12-16" Type="SCV" Version="1" SubmitterName="Eurofins Ntd Llc (ga)" OrgID="500060" OrganizationCategory="laboratory" OrgAbbreviation="EGL" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2018-04-27">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">EGL ClinVar v180209 classification definitions</Attribute>
          <Citation>
            <URL>https://submit.ncbi.nlm.nih.gov/ft/byid/kvqgb2ud/egl_clinvar_v180209_classification_definitions.pdf</URL>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
              <Gender>mixed</Gender>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="VariantAlleles" integerValue="2" />
            </ObservedData>
            <ObservedData>
              <Attribute Type="SingleHeterozygote" integerValue="2" />
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="GAA" />
          </GeneList>
          <VariantType>Deletion</VariantType>
          <Location>
            <SequenceLocation Assembly="GRCh37" Chr="17" alternateAllele="-" referenceAllele="CG" start="78092460" stop="78092461" variantLength="2" />
            <GeneLocation>NM_000152.3:Ex19</GeneLocation>
          </Location>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <Name>
              <ElementValue Type="Preferred">not provided</ElementValue>
            </Name>
          </Trait>
        </TraitSet>
        <Citation>
          <URL>http://www.egl-eurofins.com/emvclass/emvclass.php?approved_symbol=GAA</URL>
        </Citation>
        <SubmissionNameList>
          <SubmissionName>SUB4534263</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion FDARecognizedDatabase="true" ID="3987400" SubmissionDate="2021-12-02" DateLastUpdated="2021-12-12" DateCreated="2021-12-12">
        <ClinVarSubmissionID localKey="73dc276a-44f8-4f4e-ad99-3769378ea110" localKeyIsSubmitted="1" submittedAssembly="GRCh38" />
        <ClinVarAccession Accession="SCV002032121" DateUpdated="2021-12-12" DateCreated="2021-12-12" Type="SCV" Version="1" SubmitterName="ClinGen Lysosomal Storage Disorder Variant Curation Expert Panel" OrgID="507522" OrganizationCategory="consortium" OrgAbbreviation="LSD VCEP" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2021-09-01">
          <ReviewStatus>reviewed by expert panel</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Citation>
            <URL>https://erepo.clinicalgenome.org/evrepo/ui/interpretation/73dc276a-44f8-4f4e-ad99-3769378ea110</URL>
          </Citation>
          <Comment>The NM_000152.5:c.2655_2656del (p.Val886GlufsTer2) variant in GAA is a frameshift variant predicted to cause a premature stop codon and to lead to nonsense mediated decay in a gene in which loss-of-function is an established disease mechanism (PVS1). Two siblings with this variant and late-onset Pompe disease have been reported with GAA activity in dried blood spots below the normal range, and both are on enzyme replacement therapy (PMID 31392188, personal communication)(PP4_Moderate). These individuals are compound heterozygous for the variant and a pathogenic variant in GAA, c.-32-13T&gt;G, phase unknown (PM3_Supporting). The variant is absent in gnomAD v2.1.1 (PM2_Supporting). There is a ClinVar entry for this variant (Variation ID: 597005; 1 star review status) with one submitter classifying the variant as pathogenic. In summary, this variant meets the criteria to be classified as pathogenic for Pompe disease. GAA-specific ACMG/AMP criteria met, based on the specifications of the ClinGen LSD VCEP (Specifications Version 2.0): PVS1, PP4_Moderate, PM2_Supporting, PM3_Supporting.</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="ModeOfInheritance">Autosomal recessive inheritance</Attribute>
        </AttributeSet>
        <AttributeSet>
          <Attribute Type="AssertionMethod">clingen_lsd_acmg_specifications_v2-1</Attribute>
          <Citation>
            <URL>https://submit.ncbi.nlm.nih.gov/ft/byid/tb34awle/clingen_lsd_acmg_specifications_v2-1.pdf</URL>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>curation</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="GAA" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <OtherNameList>
            <Name>NM_000152.5(GAA):c.2655_2656del</Name>
            <Name>p.Val886fs</Name>
          </OtherNameList>
          <AttributeSet>
            <Attribute Type="HGVS">NC_000017.11:g.80118661_80118662del</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="MONDO" ID="MONDO:0009290" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB10749839</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
    </ClinicalAssertionList>
    <TraitMappingList>
      <TraitMapping ClinicalAssertionID="1677994" TraitType="Disease" MappingType="Name" MappingValue="not provided" MappingRef="Preferred">
        <MedGen CUI="CN517202" Name="not provided" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="3987400" TraitType="Disease" MappingType="XRef" MappingValue="MONDO:0009290" MappingRef="MONDO">
        <MedGen CUI="C0017921" Name="Glycogen storage disease, type II" />
      </TraitMapping>
    </TraitMappingList>
  </ClassifiedRecord>
</VariationArchive>

